JP6333843B2 - 明確な立体化学を有する環状プリンジヌクレオチドを含む組成物ならびにそれらの調製および使用方法 - Google Patents

明確な立体化学を有する環状プリンジヌクレオチドを含む組成物ならびにそれらの調製および使用方法 Download PDF

Info

Publication number
JP6333843B2
JP6333843B2 JP2015548023A JP2015548023A JP6333843B2 JP 6333843 B2 JP6333843 B2 JP 6333843B2 JP 2015548023 A JP2015548023 A JP 2015548023A JP 2015548023 A JP2015548023 A JP 2015548023A JP 6333843 B2 JP6333843 B2 JP 6333843B2
Authority
JP
Japan
Prior art keywords
cells
composition
cell
gmp
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015548023A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503029A5 (enExample
JP2016503029A (ja
Inventor
ダベンスキー，ジュニア，トーマス，ダブリュー．
カンネ，デービッド，ビー．
リン レオン，メレディス，ライ
リン レオン，メレディス，ライ
レメンズ，エドワード，エミール
グリックマン，ローラ，ヒックス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chinook Therapeutics Inc
Original Assignee
Chinook Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chinook Therapeutics Inc filed Critical Chinook Therapeutics Inc
Publication of JP2016503029A publication Critical patent/JP2016503029A/ja
Publication of JP2016503029A5 publication Critical patent/JP2016503029A5/ja
Application granted granted Critical
Publication of JP6333843B2 publication Critical patent/JP6333843B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2015548023A 2012-12-13 2013-12-13 明確な立体化学を有する環状プリンジヌクレオチドを含む組成物ならびにそれらの調製および使用方法 Expired - Fee Related JP6333843B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261737006P 2012-12-13 2012-12-13
US61/737,006 2012-12-13
US201361790514P 2013-03-15 2013-03-15
US61/790,514 2013-03-15
PCT/US2013/075189 WO2014093936A1 (en) 2012-12-13 2013-12-13 Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018084405A Division JP6704012B2 (ja) 2012-12-13 2018-04-25 明確な立体化学を有する環状プリンジヌクレオチドを含む組成物ならびにそれらの調製および使用方法

Publications (3)

Publication Number Publication Date
JP2016503029A JP2016503029A (ja) 2016-02-01
JP2016503029A5 JP2016503029A5 (enExample) 2017-02-16
JP6333843B2 true JP6333843B2 (ja) 2018-05-30

Family

ID=50935019

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015548023A Expired - Fee Related JP6333843B2 (ja) 2012-12-13 2013-12-13 明確な立体化学を有する環状プリンジヌクレオチドを含む組成物ならびにそれらの調製および使用方法
JP2018084405A Active JP6704012B2 (ja) 2012-12-13 2018-04-25 明確な立体化学を有する環状プリンジヌクレオチドを含む組成物ならびにそれらの調製および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018084405A Active JP6704012B2 (ja) 2012-12-13 2018-04-25 明確な立体化学を有する環状プリンジヌクレオチドを含む組成物ならびにそれらの調製および使用方法

Country Status (18)

Country Link
US (2) US9695212B2 (enExample)
EP (2) EP3527579A1 (enExample)
JP (2) JP6333843B2 (enExample)
KR (1) KR20150095668A (enExample)
CN (2) CN108542913A (enExample)
AU (2) AU2013358892B2 (enExample)
BR (1) BR112015013440B1 (enExample)
CA (1) CA2886456A1 (enExample)
DK (1) DK2931738T3 (enExample)
EA (1) EA201590396A1 (enExample)
ES (1) ES2718910T3 (enExample)
HU (1) HUE043262T2 (enExample)
MX (1) MX361680B (enExample)
PL (1) PL2931738T3 (enExample)
PT (1) PT2931738T (enExample)
SG (2) SG11201502796RA (enExample)
SI (1) SI2931738T1 (enExample)
WO (1) WO2014093936A1 (enExample)

Families Citing this family (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107648668B (zh) 2010-10-06 2021-06-18 哈佛学院董事会 用于基于材料的细胞疗法的可注射的成孔水凝胶
AU2013271375B2 (en) 2012-06-08 2018-03-22 Aduro Biotech, Inc. Compositions and methods for cancer immunotherapy
AU2013358892B2 (en) 2012-12-13 2018-06-21 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
KR102255996B1 (ko) 2012-12-19 2021-05-26 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 포유동물 시클릭 디-뉴클레오티드 신호 경로의 약학적 표적화
JP2016524593A (ja) 2013-04-29 2016-08-18 メモリアル スローン−ケタリング キャンサー センター セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
ES2822584T3 (es) * 2013-05-03 2021-05-04 Univ California Inducción de dinucleótidos cíclicos del interferón tipo I
WO2014189806A1 (en) * 2013-05-18 2014-11-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
PE20160080A1 (es) 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
WO2015017652A1 (en) 2013-07-31 2015-02-05 Memorial Sloan-Kettering Cancer Center Sting crystals and modulators
EP3071209A4 (en) * 2013-11-19 2017-08-16 The University of Chicago Use of sting agonist as cancer treatment
CN103908468B (zh) * 2014-04-21 2017-02-08 上海捌加壹医药科技有限公司 环二核苷酸cGAMP在制备抗肿瘤药物中的应用
US10682400B2 (en) 2014-04-30 2020-06-16 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
JP6462006B2 (ja) 2014-06-04 2019-01-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｓｔｉｎｇのモジュレーターとしての環式ジヌクレオチド
US11058758B2 (en) 2014-11-20 2021-07-13 National Institutes Of Biomedical Innovation, Health And Nutrition TH1-inducing adjuvant comprising combination of different nucleic acid adjuvants, and use of same
CN107148424B (zh) 2014-12-16 2021-01-08 凯拉治疗股份公司 用于诱导细胞因子的环状二核苷酸
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
WO2016130616A1 (en) 2015-02-11 2016-08-18 The Johns Hopkins University Bacteria over-expressing c-di-amp and therapeutic methods
US10449211B2 (en) * 2015-03-10 2019-10-22 Aduro Biotech, Inc. Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
CA2988086C (en) 2015-06-03 2023-09-19 The Medical College Of Wisconsin, Inc. An engineered ccl20 locked dimer polypeptide
US11571462B2 (en) 2015-06-03 2023-02-07 The Medical College Of Wisconsin, Inc. Engineered CCL20 locked dimer polypeptide
EA034786B1 (ru) 2015-08-13 2020-03-20 Мерк Шарп И Доум Корп. Циклические динуклеотидные соединения в качестве агонистов sting
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
HK1257840A1 (zh) 2015-09-01 2019-11-01 Agenus Inc. 抗-pd-1抗体及其使用方法
CN105367617A (zh) * 2015-09-25 2016-03-02 武汉品生科技有限公司 一种基于环二腺核苷酸的衍生物、tat多肽及其在一型干扰素小分子中抑制剂的应用
EP3368072A4 (en) * 2015-10-28 2019-07-03 Aduro BioTech, Inc. COMPOSITIONS AND METHOD FOR ACTIVATING SIGNALING DEPENDENT ON THE STIMULATOR OF THE INTERFERON GENE
CN106539813B (zh) * 2015-11-30 2019-12-03 杭州星鳌生物科技有限公司 干扰素刺激基因(sting)激活剂在抗炎症中的应用
RU2020113165A (ru) * 2015-12-03 2020-06-09 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Циклические пуриновые динуклеотиды в качестве модуляторов sting
CN106539814A (zh) * 2015-12-09 2017-03-29 聊城市奥润生物医药科技有限公司 干扰素基因刺激蛋白（sting）激动剂在抗类风湿性关节炎等疾病中的应用
CN106540260A (zh) * 2015-12-09 2017-03-29 聊城市奥润生物医药科技有限公司 干扰素基因刺激蛋白（sting）激动剂在抗阿尔兹海默症中的应用
CN106554416B (zh) * 2015-12-09 2019-03-15 聊城市奥润生物医药科技有限公司 一种抗pd-l1人源化单克隆抗体联合干扰素基因刺激蛋白（sting）激动剂在抗肿瘤中的应用
US20180369268A1 (en) * 2015-12-16 2018-12-27 Aduro Biotech, Inc. Methods for identifying inhibitors of "stimulator of interferon gene"- dependent interferon production
CN108601731A (zh) 2015-12-16 2018-09-28 磨石肿瘤生物技术公司 新抗原的鉴别、制造及使用
SMT202500412T1 (it) 2016-01-11 2025-11-10 Innate Tumor Immunity Inc Dinucleotidi ciclici per il trattamento di condizioni associate all’attività di sting quali il cancro
AU2017225769B2 (en) * 2016-03-02 2023-01-05 The Board Of Regents Of The University Of Texas System Sting activating nanovaccine for immunotherapy
NZ746112A (en) 2016-03-18 2023-01-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
CN106539757A (zh) * 2016-03-20 2017-03-29 聊城市奥润生物医药科技有限公司 环二核苷酸cGAMP-脂质体在抗肿瘤中的应用
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ タンパク質調節物質として有用な複素環アミド
CN113549110B (zh) 2016-04-07 2024-08-16 葛兰素史密斯克莱知识产权发展有限公司 用作蛋白质调节剂的杂环酰胺
WO2017186711A1 (en) 2016-04-25 2017-11-02 Invivogen Novel complexes of immunostimulatory compounds, and uses thereof
US10696985B1 (en) 2016-06-06 2020-06-30 Vanderbilt University Reversibly crosslinked endosomolytic polymer vesicles for cytosolic drug delivery
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
AU2017293781B2 (en) * 2016-07-06 2022-12-22 Invox Pharma Limited Compounds, compositions, and methods for the treatment of disease
WO2018013924A1 (en) 2016-07-15 2018-01-18 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
DE102016113714A1 (de) 2016-07-26 2018-02-01 Rosa Karl Transfektionsverfahren mit nicht-viralen Genliefersystemen
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
EP3493842A4 (en) 2016-08-02 2020-07-29 President and Fellows of Harvard College BIOMATERIALS TO MODULATE IMMUNE RESPONSES
KR102497742B1 (ko) 2016-08-30 2023-02-10 다나-파버 캔서 인스티튜트 인크. 약물 전달 조성물 및 그의 용도
WO2018053508A1 (en) * 2016-09-19 2018-03-22 The University Of North Carolina At Chapel Hill Methods and compositions for inducing an immune response
US10537590B2 (en) 2016-09-30 2020-01-21 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds
TN2020000158A1 (en) 2016-10-04 2022-04-04 Merck Sharp & Dohme BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
US10266558B2 (en) * 2016-10-07 2019-04-23 Alexandre Vasilievich Ivachtchenko Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof
EP3523314A1 (de) 2016-10-07 2019-08-14 Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb GmbH Benzimidazolhaltige cyclische dinukleotide, verfahren zu deren herstellung und ihre verwendung zur aktivierung von stimulator von interferongenen (sting)-abhängigen signalwegen
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
EP3551225A1 (en) 2016-12-07 2019-10-16 Agenus Inc. Antibodies and methods of use thereof
WO2018119117A1 (en) * 2016-12-22 2018-06-28 The Regents Of The University Of California Methods of producing cyclic dinucleotides
JP2018131427A (ja) * 2017-02-17 2018-08-23 国立研究開発法人理化学研究所 免疫細胞の制御技術
US20200055883A1 (en) 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
EP3585379A4 (en) 2017-02-21 2020-12-02 Board of Regents, The University of Texas System CYCLIC DINUCLEOTIDES USED AS AGONISTS OF THE INTERFERON-DEPENDENT SIGNALING STIMULATOR
CN106928298B (zh) * 2017-03-13 2021-10-22 杭州星鳌生物科技有限公司 环二核苷酸cGAMP衍生物的结构组成、制备方法及其在抗肿瘤中的应用
JOP20190218A1 (ar) * 2017-03-22 2019-09-22 Boehringer Ingelheim Int مركبات ثنائية النيوكليوتيدات حلقية معدلة
SG11201908813QA (en) 2017-04-13 2019-10-30 Aduro Biotech Holdings Europe B V Anti-sirp alpha antibodies
AU2018252193B2 (en) 2017-04-14 2024-12-12 Tallac Therapeutics, Inc. Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
EP3621624B1 (en) 2017-05-12 2023-08-30 Merck Sharp & Dohme LLC Cyclic di-nucleotide compounds as sting agonists
WO2018232217A1 (en) 2017-06-16 2018-12-20 William Marsh Rice University Hydrogel delivery of sting immunotherapy for treatment of cancer
US11285131B2 (en) 2017-08-04 2022-03-29 Merck Sharp & Dohme Corp. Benzo[b]thiophene STING agonists for cancer treatment
RU2020109328A (ru) 2017-08-04 2021-09-06 Мерк Шарп И Доум Корп. Комбинации антагонистов pd-1 и бензо[b]тиофеновых агонистов sting для лечения рака
CN111263767B (zh) 2017-08-30 2023-07-18 北京轩义医药科技有限公司 作为干扰素基因调节剂的刺激剂的环状二核苷酸
CA3074232A1 (en) 2017-08-31 2019-03-07 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
US11707531B2 (en) 2017-09-11 2023-07-25 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
WO2019051488A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
JP7654240B2 (ja) 2017-09-19 2025-04-01 マサチューセッツ インスティテュート オブ テクノロジー キメラ抗原受容体ｔ細胞治療のための組成物およびその使用
JP2020536106A (ja) 2017-10-05 2020-12-10 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｈｉｖの処置に有用なインターフェロン遺伝子の刺激物質（ｓｔｉｎｇ）の調節物質
BR112020006780A2 (pt) 2017-10-05 2020-10-06 Glaxosmithkline Intellectual Property Development Limited moduladores do estimulador de genes do interferon (sting)
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
CN111566119A (zh) 2017-11-10 2020-08-21 武田药品工业有限公司 Sting调节剂化合物以及制备和使用方法
US11673891B2 (en) 2017-11-14 2023-06-13 Dana-Farber Cancer Institute, Inc. Imidazopyrimidine compounds and uses thereof
JP7382316B2 (ja) * 2017-11-14 2023-11-16 ザ チルドレンズ メディカル センター コーポレーション ヒト免疫応答をモジュレートするためのイミダゾピリミジンの使用
EP3714275A4 (en) 2017-11-22 2021-10-27 Gritstone bio, Inc. REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2019125974A1 (en) 2017-12-20 2019-06-27 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
US12065649B2 (en) 2018-01-09 2024-08-20 Vanderbilt University Pattern recognition receptor agonist prodrugs and methods of use thereof
US12220462B1 (en) 2018-02-13 2025-02-11 Abionyx Pharma Sa Complexes for delivery of cyclic dinucleotides
WO2019161171A1 (en) * 2018-02-16 2019-08-22 Sperovie Biosciences, Inc. Nanoparticle formulations of sting agonists
EP3768310A1 (en) 2018-03-23 2021-01-27 Codiak BioSciences, Inc. Extracellular vesicles comprising sting-agonist
JP2021519279A (ja) 2018-03-27 2021-08-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 修飾環式ジヌクレオチド化合物
JP2021519270A (ja) 2018-03-27 2021-08-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ２−アザ−ヒポキサンチンまたは６ｈ−ピラゾロ［１，５−ｄ］［１，２，４］トリアジン−７−オンをｓｔｉｎｇアゴニストとして含む環式ジヌクレオチド化合物
WO2019195063A1 (en) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Aza-benzothiophene compounds as sting agonists
WO2019195124A1 (en) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Benzothiophenes and related compounds as sting agonists
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
ES2929415T3 (es) 2018-05-25 2022-11-29 Incyte Corp Compuestos heterocíclicos tricíclicos como activadores de STING
CN112512531B (zh) 2018-06-01 2024-04-09 卫材R&D管理有限公司 用于膀胱癌的治疗的方法
CA3106110A1 (en) 2018-07-10 2020-01-16 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
WO2020028565A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Tricyclic heteraryl compounds as sting activators
WO2020028566A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Heteroaryl amide compounds as sting activators
CA3107263A1 (en) * 2018-08-03 2020-02-06 The University Of Tokyo Nasal vaccine that induces cell-mediated immunity
MX2020013322A (es) 2018-08-16 2021-02-22 Eisai R&D Man Co Ltd Sales de compuestos y cristales de los mismos.
KR102567590B1 (ko) 2018-09-06 2023-08-17 다이이찌 산쿄 가부시키가이샤 신규 고리형 디뉴클레오티드 유도체 및 그 항체 약물 콘쥬게이트
US20220031825A1 (en) * 2018-09-17 2022-02-03 Quratis Inc. Immunological adjuvant and vaccine composition including sting agonist
KR102755652B1 (ko) 2018-09-21 2025-01-21 상하이 드 노보 파마테크 컴퍼니 리미티드 고리형 디뉴클레오티드 유사체, 이의 약학 조성물 및 용도
US11110106B2 (en) 2018-10-29 2021-09-07 Venenum Biodesign, LLC Sting agonists for treating bladder cancer and solid tumors
AU2019371206A1 (en) 2018-10-29 2021-05-27 Venenum Biodesign, LLC Novel sting agonists
US20220008346A1 (en) 2018-10-30 2022-01-13 Vanderbilt University Graft copolymers, methods of forming graft copolymers, and methods of use thereof
JP2022509929A (ja) 2018-10-31 2022-01-25 ノバルティス アーゲー Ｓｔｉｎｇアゴニストを含むｄｃ－ｓｉｇｎ抗体コンジュゲート
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
WO2020146237A1 (en) 2019-01-07 2020-07-16 Incyte Corporation Heteroaryl amide compounds as sting activators
CN111423483B (zh) * 2019-01-10 2025-01-17 英诺生物制药(深圳)有限公司 环二核苷酸前药分子及其制备方法和应用
DK3934757T3 (da) 2019-03-07 2023-04-17 Inst Of Organic Chemistry And Biochemistry Ascr V V I 2'3'-cykliske dinukleotider og prodrugs deraf
AU2020231115B2 (en) 2019-03-07 2025-02-20 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
SG11202109702QA (en) 2019-03-21 2021-10-28 Codiak Biosciences Inc Extracellular vesicles for vaccine delivery
US20240108747A1 (en) 2019-03-21 2024-04-04 Lonza Sales Ag Extracellular vesicle conjugates and uses thereof
US12233356B2 (en) 2019-03-21 2025-02-25 Lonza Sales Ag Process for preparing extracellular vesicles
EP3946324B1 (en) 2019-04-04 2025-07-30 Merck Sharp & Dohme LLC Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
TW202104214A (zh) 2019-04-05 2021-02-01 英商葛蘭素史密斯克藍智慧財產發展有限公司 化合物
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
JP7621974B2 (ja) 2019-05-09 2025-01-27 アリゴス セラピューティクス インコーポレイテッド Ｓｔｉｎｇモジュレータとしての修飾環状ジヌクレオシド化合物
IL287938B2 (en) 2019-05-10 2025-07-01 Takeda Pharmaceuticals Co Antibody-drug conjugates
WO2021003445A1 (en) 2019-07-03 2021-01-07 Codiak Biosciences, Inc. Extracellular vesicles targeting t cells and uses thereof
US20230181758A1 (en) 2019-07-03 2023-06-15 Codiak Biosciences, Inc. Extracellular vesicles targeting dendritic cells and uses thereof
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
KR20220056176A (ko) 2019-08-02 2022-05-04 메르사나 테라퓨틱스, 인코포레이티드 암 치료를 위한 sting(인터페론 유전자의 자극인자) 작용제로서의 비스-[n-((5-카바모일)-1h-벤조[d]이미다졸-2-일)-피라졸-5-카복사미드] 유도체 및 관련 화합물
CN114127121B (zh) 2019-08-12 2025-04-11 北京恩瑞尼生物科技股份有限公司 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
EP3785719A1 (en) * 2019-08-28 2021-03-03 Helmholtz-Zentrum für Infektionsforschung GmbH New use of cyclic dinucleotides
EP4034081A1 (en) 2019-09-25 2022-08-03 Codiak BioSciences, Inc. Extracellular vesicle compositions
US20230241089A1 (en) 2019-09-25 2023-08-03 Codiak Biosciences, Inc. Sting agonist comprising exosomes for treating neuroimmunological disorders
WO2021062290A1 (en) 2019-09-25 2021-04-01 Codiak Biosciences, Inc. Methods of producing extracellular vesicles
JP2022551420A (ja) 2019-09-25 2022-12-09 コディアック バイオサイエンシーズ， インコーポレイテッド 腫瘍を治療するためのｉｌ－１２提示エクソソームとｓｔｉｎｇアゴニスト含有エクソソームとの併用
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
EP4069683A1 (en) 2019-12-06 2022-10-12 Mersana Therapeutics, Inc. Dimeric compounds as sting agonists
CN114981265B (zh) 2019-12-18 2025-01-03 Ctxt私人有限公司 化合物
US12251449B2 (en) 2019-12-19 2025-03-18 William Marsh Rice University Synthetic multidomain peptide biomaterials that inhibit inducible nitric oxide synthase
AU2020407871A1 (en) 2019-12-20 2022-06-30 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing toll-like receptor ("TLR") agonist prodrugs useful in the treatment of cancer and methods thereof
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
US11920136B2 (en) 2020-02-28 2024-03-05 Tallac Therapeutics, Inc. Transglutaminase-mediated conjugation
BR112022015283A2 (pt) 2020-03-06 2022-09-20 Daiichi Sankyo Co Ltd Conjugado anticorpo-fármaco incluindo derivados de dinucleotídeos cíclicos
EP4117717A1 (en) 2020-03-13 2023-01-18 Codiak BioSciences, Inc. Extracellular vesicles for treating neurological disorders
EP4121450A2 (en) 2020-03-20 2023-01-25 Codiak BioSciences, Inc. Extracellular vesicles for therapy
MY210304A (en) 2020-04-02 2025-09-10 Mersana Therapeutics Inc Antibody drug conjugates comprising sting agonists
TW202200136A (zh) 2020-04-10 2022-01-01 日商小野藥品工業股份有限公司 癌治療方法
US20230149560A1 (en) 2020-04-20 2023-05-18 Massachusetts Institute Of Technology Lipid compositions for delivery of sting agonist compounds and uses thereof
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US12433954B2 (en) 2020-05-01 2025-10-07 Massachusetts Institute Of Technology Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
CN115835856A (zh) 2020-05-13 2023-03-21 麻省理工学院 聚合物微装置的组合物以及其在癌症免疫疗法中的用途
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
CN116209678A (zh) 2020-07-01 2023-06-02 安尔士制药公司 抗asgr1抗体缀合物及其用途
KR20230061360A (ko) 2020-09-02 2023-05-08 다이이찌 산쿄 가부시키가이샤 신규 엔도-β-N-아세틸글루코사미니다아제
WO2022066934A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
WO2022066883A1 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Extracellular vesicles comprising kras antigens and uses thereof
WO2022066928A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
EP4216993A2 (en) 2020-09-23 2023-08-02 Codiak BioSciences, Inc. Methods of producing extracellular vesicles
WO2022079175A1 (en) 2020-10-14 2022-04-21 Boehringer Ingelheim International Gmbh Combination of a sting agonist and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist
AU2021363267A1 (en) * 2020-10-20 2023-06-22 Tyligand Bioscience (Shanghai) Limited Multifunctional cyclic dinucleotide and use thereof
EP4240488A1 (en) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Antibody drug conjugates
JP2023554396A (ja) 2020-12-17 2023-12-27 トラスティーズ オブ タフツ カレッジ Ｆａｐ活性化ラジオセラノスティクスおよび関連する使用
EP4032545A1 (en) * 2021-01-26 2022-07-27 Medizinische Hochschule Hannover Immunogenic composition and vaccine containing chlamydia ssp. surface antigens and its use
JP2024514707A (ja) 2021-04-20 2024-04-02 アンスティテュ・クリー 免疫療法における使用のための組成物及び方法
WO2022223622A1 (en) 2021-04-20 2022-10-27 Institut Curie Compositions and methods for use in immunotherapy
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
WO2023056468A1 (en) 2021-09-30 2023-04-06 Codiak Biosciences, Inc. Extracellular vesicle comprising cholesterol tagged sting-agonist
EP4413038A1 (en) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Pd-l1 binding affimers
TW202346322A (zh) 2022-03-02 2023-12-01 日商第一三共股份有限公司 含Ｆｃ分子之製造方法
US20230414763A1 (en) 2022-03-04 2023-12-28 Massachusetts Institute Of Technology Transmucosal amphiphile-protein conjugate vaccine
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
EP4569129A1 (en) * 2022-08-10 2025-06-18 Aldevron, LLC Methods for producing cyclic dinucleotides
EP4582106A1 (en) 2022-08-29 2025-07-09 Daiichi Sankyo Company, Limited Antibody-drug conjugate including mutant fc region
CN115381936A (zh) * 2022-08-29 2022-11-25 福建师范大学 一种猴痘病毒疫苗
WO2024199359A1 (zh) * 2023-03-28 2024-10-03 江苏瑞科生物技术股份有限公司 包含环二核苷酸分子的脂质体佐剂系统及其制备方法
WO2024211577A1 (en) 2023-04-05 2024-10-10 Massachusetts Institute Of Technology Hybrid polymeric systems and methods of use thereof
CN116392585A (zh) * 2023-04-06 2023-07-07 中山大学孙逸仙纪念医院 一种肿瘤疫苗佐剂及其应用

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9110808D0 (en) 1991-05-17 1991-07-10 Retroscreen Ltd Aids vaccine and method for its production
GB2257704B (en) * 1991-07-18 1995-03-01 Erba Carlo Spa Cyclic oligonucleotides phosphorothioates
US5637483A (en) 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US5904920A (en) 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
IT1262895B (it) 1992-03-02 1996-07-22 Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
US5635160A (en) 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US6033674A (en) 1995-12-28 2000-03-07 Johns Hopkins University School Of Medicine Method of treating cancer with a tumor cell line having modified cytokine expression
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
AU741602B2 (en) 1998-02-02 2001-12-06 Johns Hopkins University School Of Medicine, The A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use
EP1153931B1 (en) 1999-02-15 2005-07-20 Nippon Shinyaku Co., Ltd. Shortened-chain polynucleotides and process for the preparation thereof
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
US20020150588A1 (en) 2000-09-21 2002-10-17 Allison James P. SPAS-1 cancer antigen
JP2004511527A (ja) * 2000-10-18 2004-04-15 グラクソスミスクライン　バイオロジカルズ　ソシエテ　アノニム ワクチン
US7279883B2 (en) 2001-01-23 2007-10-09 Lydia L. Sohn Particle analyzer and methods for use thereof
TW200303759A (en) 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
WO2005030186A2 (en) 2003-07-28 2005-04-07 Univ Maryland Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation
JP2007509067A (ja) 2003-10-15 2007-04-12 メディミューン，インコーポレーテッド リステリアに基づくＥｐｈＡ２ワクチン
EP1677765A1 (en) * 2003-10-24 2006-07-12 Alza Corporation Preparation of lipid particles
CA2560058C (en) 2004-03-15 2011-10-18 David K.R. Karaolis A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
US7592326B2 (en) * 2004-03-15 2009-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
EP1888790A2 (en) 2005-05-06 2008-02-20 The Regents of the University of California Microfluidic system for identifying or sizing individual particles passing through a channel
US20070059683A1 (en) 2005-09-15 2007-03-15 Tom Barber Veterinary diagnostic system
EP1782826A1 (en) * 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
JP5623016B2 (ja) 2005-12-01 2014-11-12 プロネイ・セラピューティクス・インコーポレイテッドＰｒｏｎａｉｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 癌治療法およびそれに用いる医薬組成物
US8304529B2 (en) * 2006-07-28 2012-11-06 Life Technologies Corporation Dinucleotide MRNA cap analogs
AU2007292302A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing PARP inhibitors and uses thereof
TWI444384B (zh) * 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
WO2010017248A2 (en) 2008-08-04 2010-02-11 University Of Miami Sting (stimulator of interferon genes), a regulator of innate immune responses
US8840881B2 (en) 2008-08-28 2014-09-23 Aduro Gvax Inc. Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
CA2745096C (en) 2008-12-09 2013-11-05 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
US8765171B2 (en) 2009-03-09 2014-07-01 The Regents Of The University Of California Methods and compositions for liposomal formulation of antigens and uses thereof
US8414630B2 (en) 2009-03-10 2013-04-09 Marc Evan Richelsoph Active bone screw
LT2437753T (lt) 2009-06-05 2016-12-12 Infectious Disease Research Institute Sintetiniai gliukopiranozillipidų adjuvantai ir juos turinčios vakcinų kompozicijos
WO2011003025A1 (en) * 2009-07-01 2011-01-06 Rutgers, The State University Of New Jersey Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof
US8771933B2 (en) 2009-10-06 2014-07-08 Massachusetts Institute Of Technology Continuous-flow deformability-based cell separation
KR101605932B1 (ko) * 2009-12-18 2016-03-24 노파르티스 아게 Ｈｓｆ1-관련 질환을 치료하기 위한 유기 조성물
EP2361911A1 (en) * 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
WO2011119492A2 (en) 2010-03-22 2011-09-29 Massachusetts Institute Of Technology Methods and compositions related to the measurement of material properties
CN102199183B (zh) 2010-03-26 2013-12-18 北京大学 环二鸟苷酸及其类似物和制备方法
WO2011136828A1 (en) 2010-04-27 2011-11-03 The Johns Hopkins University Immunogenic compositions and methods for treating neoplasia
US8450293B2 (en) 2010-08-10 2013-05-28 Rutgers, The State University Of New Jersey Synthesis and characterization of C8 analogs of c-di-GMP
ES2684684T3 (es) 2010-11-17 2018-10-04 Aduro Biotech, Inc. Métodos y composiciones para inducir una respuesta inmune al EGFRVIII
US9061048B2 (en) 2010-12-15 2015-06-23 The Regents Of The University Of California Cyclic di-AMP induction of type I interferon
AU2011349278C1 (en) * 2010-12-22 2017-01-19 Alios Biopharma, Inc. Cyclic nucleotide analogs
EP2697357A4 (en) 2011-04-15 2015-04-22 Univ British Columbia METHOD AND DEVICE FOR SEPARATING PARTICLES
WO2013086331A1 (en) 2011-12-07 2013-06-13 President And Fellows Of Harvard College High efficiency di-nucleotide cyclase
EP2844756A4 (en) 2012-04-30 2016-02-24 Glen N Barber MODULATION OF IMMUNE REACTIONS
AU2013271375B2 (en) 2012-06-08 2018-03-22 Aduro Biotech, Inc. Compositions and methods for cancer immunotherapy
CN103566377A (zh) * 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
US9090646B2 (en) 2012-12-05 2015-07-28 Rutgers, The State University Of New Jersey Biotinylated compounds
AU2013358892B2 (en) 2012-12-13 2018-06-21 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
KR102255996B1 (ko) 2012-12-19 2021-05-26 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 포유동물 시클릭 디-뉴클레오티드 신호 경로의 약학적 표적화
JP2016524593A (ja) 2013-04-29 2016-08-18 メモリアル スローン−ケタリング キャンサー センター セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
ES2822584T3 (es) 2013-05-03 2021-05-04 Univ California Inducción de dinucleótidos cíclicos del interferón tipo I
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
WO2014189806A1 (en) 2013-05-18 2014-11-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
PE20160080A1 (es) 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
WO2015017652A1 (en) 2013-07-31 2015-02-05 Memorial Sloan-Kettering Cancer Center Sting crystals and modulators
US9642830B2 (en) 2013-10-21 2017-05-09 Drexel University Use of sting agonists to treat hepatitis B virus infection
EP3071209A4 (en) 2013-11-19 2017-08-16 The University of Chicago Use of sting agonist as cancer treatment
WO2015074145A1 (en) 2013-11-22 2015-05-28 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
WO2015085565A1 (en) 2013-12-13 2015-06-18 Qualcomm Incorporated Methods and apparatus for cell selection in a wireless communication system
US10421971B2 (en) 2014-01-15 2019-09-24 The University Of Chicago Anti-tumor therapy
JP6462006B2 (ja) 2014-06-04 2019-01-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｓｔｉｎｇのモジュレーターとしての環式ジヌクレオチド
CN107148424B (zh) 2014-12-16 2021-01-08 凯拉治疗股份公司 用于诱导细胞因子的环状二核苷酸
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
US10449211B2 (en) * 2015-03-10 2019-10-22 Aduro Biotech, Inc. Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
EA034786B1 (ru) 2015-08-13 2020-03-20 Мерк Шарп И Доум Корп. Циклические динуклеотидные соединения в качестве агонистов sting
RU2020113165A (ru) 2015-12-03 2020-06-09 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Циклические пуриновые динуклеотиды в качестве модуляторов sting

Also Published As

Publication number Publication date
US10414789B2 (en) 2019-09-17
MX2015007447A (es) 2015-12-09
BR112015013440B1 (pt) 2020-12-08
SG11201502796RA (en) 2015-05-28
AU2018203682A1 (en) 2018-06-14
AU2018203682B2 (en) 2020-07-02
MX361680B (es) 2018-12-13
KR20150095668A (ko) 2015-08-21
ES2718910T3 (es) 2019-07-05
JP6704012B2 (ja) 2020-06-03
HK1212707A1 (zh) 2016-06-17
US9695212B2 (en) 2017-07-04
CA2886456A1 (en) 2014-06-19
US20140205653A1 (en) 2014-07-24
CN108542913A (zh) 2018-09-18
HUE043262T2 (hu) 2019-08-28
WO2014093936A1 (en) 2014-06-19
SI2931738T1 (sl) 2019-05-31
CN105008381A (zh) 2015-10-28
EA201590396A1 (ru) 2015-12-30
EP2931738A1 (en) 2015-10-21
EP3527579A1 (en) 2019-08-21
DK2931738T3 (en) 2019-04-15
PT2931738T (pt) 2019-04-10
EP2931738B1 (en) 2019-02-06
JP2016503029A (ja) 2016-02-01
JP2018135367A (ja) 2018-08-30
AU2013358892A1 (en) 2015-05-21
BR112015013440A2 (pt) 2017-07-11
EP2931738A4 (en) 2016-04-27
SG10201704611WA (en) 2017-07-28
PL2931738T3 (pl) 2019-07-31
NZ707561A (en) 2020-11-27
US20170283454A1 (en) 2017-10-05
CN105008381B (zh) 2018-08-07
AU2013358892B2 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
JP6704012B2 (ja) 明確な立体化学を有する環状プリンジヌクレオチドを含む組成物ならびにそれらの調製および使用方法
JP6453855B2 (ja) 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を活性化するための組成物及び方法
US9770467B2 (en) Compositions and methods for cancer immunotherapy
HK40013049A (en) Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
HK1259906A1 (en) Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
HK1212707B (zh) 包含具有确定立体化学的环嘌呤二核苷酸的组合物及其制备和使用方法
NZ707561B2 (en) Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
HK1219024B (zh) 用於活化“干扰素基因刺激因子”-依赖性信号传导的组合物和方法
HK1222512B (en) Compositions and methods for activating "stimulator of interferon gene"-dependent signalling

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180130

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180327

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180425

R150 Certificate of patent or registration of utility model

Ref document number: 6333843

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees